“Not Approvable” Letter Leaves Vanda’s Schizophrenia Drug With Cloudy Future

FDA requests additional Phase III comparative study and safety data for iloperidone.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet